AI-powered antibody discovery combining computational screening with phage display, single B-cell cloning, and NGS antibody sequencing. Lead identification against any target in 6–10 weeks.
Antibody discovery is the starting point of every therapeutic and diagnostic program. The quality of the discovery process — the diversity of antibodies screened, the stringency of selection, and the accuracy of hit characterization — directly determines whether a program progresses or stalls.
AntibodyLLM's discovery platform combines the power of AI with rigorous experimental validation. Rather than choosing between computational and wet-lab approaches, we deploy them in parallel: AI generates and pre-screens thousands of candidates in silico; experimental platforms (phage display, single B-cell) independently identify binding hits; AI then integrates both datasets to select the optimal leads for further development.
Our antibody sequencing capabilities complement discovery for clients who already have binding antibodies from hybridomas or previous programs. Converting hybridoma antibodies to recombinant sequences protects against supply disruption, enables engineering modifications, and creates a definitive IP asset. We also offer deep B-cell receptor repertoire sequencing for clients pursuing next-generation discovery approaches.
Our LLM generates antibody sequences computationally against your target without requiring immunization. Best for: difficult targets, rapid iteration, bispecific design, and programs where time is critical. Delivers candidates in 2–4 weeks.
Panning of synthetic scFv or Fab libraries (>1010 diversity) against recombinant antigen, cell surface-expressed targets, or native protein. AI-guided biopanning strategy and hit analysis. Delivers 50–200 unique binding sequences.
FACS-based isolation of antigen-specific B cells from immunized mice or human donors, followed by single-cell RT-PCR and sequencing of paired VH/VL. Preserves native heavy-light chain pairing lost in phage display.
What is antibody sequencing? It is the determination of the precise variable region sequences (VH and VL) of an antibody — from hybridoma cells, purified protein, or B-cell populations. AntibodyLLM achieves a 99% antibody sequencing success rate across all sample types and platforms, making it the highest in the industry.
Sequence-Verified Before Delivery
We do not release raw sequence data. Every sequence undergoes recombinant expression verification and bioactivity confirmation in our in-house weblab before the final report is delivered. One-stop service: sample in → sequencing → expression → bioactivity validation → verified delivery. No third parties.
| Method | Best For | Turnaround | Output |
|---|---|---|---|
| 5' RACE + Sanger | Hybridoma sequencing, unknown V-gene | 1–2 weeks | Confirmed VH/VL sequence |
| Proteomics (MS-based) | De novo sequencing from protein, no RNA | 3–4 weeks | High-coverage peptide sequence |
| NGS Repertoire Sequencing | Immune repertoire profiling, library diversity | 2–3 weeks | Thousands of unique VH/VL pairs |
AntibodyLLM's fully integrated platform handles the complete antibody development journey. Once lead antibodies are identified through discovery, our pipeline moves seamlessly into:
Antibody discovery involves identifying naturally occurring or library-derived antibodies that bind a target — typically through immunization, phage display, or B-cell isolation. Antibody design (as offered in our AI design service) generates entirely novel sequences computationally without relying on biological immune responses. AntibodyLLM's integrated platform uses both: AI design for speed and difficult targets, experimental discovery for diversity and naturally matured affinities.
Hybridoma cells can drift, lose productivity, or die — taking your antibody with them. Sequencing converts your hybridoma antibody to a permanent, reproducible recombinant sequence. Benefits: sequence is your IP asset; recombinant production delivers lot-to-lot consistency hybridomas cannot; sequence enables humanization or engineering; and you can switch manufacturers without dependency on a specific hybridoma cell bank.
For solid-phase panning, we require 0.5–2 mg of purified recombinant antigen with a capture tag (His, Fc, biotin). For cell-based panning (membrane proteins, receptor complexes), target-expressing cell lines are used. AntibodyLLM can also produce the antigen via our recombinant protein expression service if you only have a gene sequence.
A standard phage display campaign delivers 20–50 unique, confirmed binders after AI-guided down-selection from hundreds of hits. AI de novo design campaigns deliver 5–20 candidates. All leads are delivered with confirmed VH/VL sequences, binding data, and a comparative ranking report. Additional leads can be requested based on different epitope coverage or affinity requirements.
AntibodyLLM achieves a 99% overall antibody sequencing success rate across all sample types and methods — hybridoma cells, purified protein, and B-cell populations. This rate reflects completed, verified sequence delivery: every result is expression-confirmed and bioactivity-validated in our in-house weblab before handover. We do not count unverified sequences as successes. For the most challenging scenario — de novo LC-MS/MS sequencing from purified protein with no RNA or cells — success rate is >90% for well-purified IgG samples at ≥0.1 mg input.
Yes. If only purified antibody protein is available (no cells or RNA), we offer proteomics-based de novo sequencing using LC-MS/MS. The antibody is digested with multiple proteases, and peptide MS/MS data is assembled computationally to recover the full VH/VL sequence. Success rate is >90% for well-purified IgG samples at ≥0.1 mg input. For samples with intact hybridoma cells or RNA, our overall sequencing success rate is 99% — using 5' RACE + Sanger or NGS matched to your sample type.
NGS repertoire sequencing profiles thousands of unique antibody sequences from B cells in a single experiment. Applications include: tracking immune response evolution during immunization campaigns (to identify optimal bleed timing), discovering rare high-affinity clones missed by standard hybridoma screening, characterizing diversity of phage display libraries, and precision immunology research (B-cell clonal dynamics in disease).
Tell us your target antigen and discovery goals. We'll recommend the optimal approach and provide a project proposal within 48 hours.
Discuss Your Target